A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 4, 2006, Pages 412-426

  Latz, Jane E ^a   Karlsson, Mats O ^b   Rusthoven, James J ^c   Ghosh, Atalanta ^a   Johnson, Robert D ^d  

^a ELI LILLY AND COMPANY   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c MCMASTER UNIVERSITY   (Canada)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Alimta; Hematologic toxicity; Neutropenia; NONMEM; Pemetrexed; Population pharmacodynamics; Semimechanistic physiologic

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; BOVINE SERUM ALBUMIN; CITRIC ACID; CYANOCOBALAMIN; CYSTATHIONINE; FOLIC ACID; HOMOCYSTEINE; METHYLMALONIC ACID; PEMETREXED; PROTEIN; PYRIDOXINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; BODY SURFACE; CANCER CHEMOTHERAPY; COVARIANCE; DATA ANALYSIS; FEMALE; HEMATOPOIESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL MODEL; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADULT; AGED; ALGORITHMS; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; AVITAMINOSIS; BLOOD CELL COUNT; BODY SURFACE AREA; CLINICAL TRIALS, PHASE II; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEUTROPENIA; NEUTROPHILS; POPULATION; VITAMIN B 12; VITAMIN B 6; VITAMINS;

EID: 30644468229     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0077-5     Document Type: Article

References (55)

1. Adjei AA (2003) Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 3:145-156
2. Alati T, Shih C, Pohland RC, Lantz FJ, Grindey GB (1992) Evaluation of the mechanism(s) of inhibition of the toxicity, but not the antitumor activity of lomotrexol (DDATHF) by folic acid. Proc Am Assoc Cancer Res 33:407
3. Alimta Drug Approval Package, Medical Review. Food and Drug Administration Web site. Available at: http://www.fda.-gov/cder/foi/nda/2004/21- 462.pdf_Alimta_Medr_P6.pdf. Page 257. Accessed September 20, 2004
4. 12) and folate deficiency. FASEB J 7:1344-1353
5. Bajetta E, Celio L, Buzzoni R et al (2003) Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol 14:1543-1548
6. Beal SL, Sheiner LB (1982) Estimating population kinetics. Crit Rev Biomed Eng 8:195-222
7. Beal SL, Sheiner LB (1988) Heterskedastic nonlinear regression. Technometrics 30:327-338
8. Beal SL, Sheiner LB (1992) NONMEM user's guide NONMEM project group. University of California, San Francisco
9. Branda RF, Nigels E, Lafayette AR, Hacker M (1998) Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats. Blood 92:2471-2476
10. Branda RF, Chen Z, Brooks EM, Naud SJ, Trainer TD, McCormack JJ (2002) Diet modulates the toxicity of cancer chemotherapy in rats. J Lab Clin Med 140:358-368
11. 12, folate, and dietary supplements on breast carcinoma chemotherapy-induced mucositis and neutropenia. Cancer 101:1058-1064
12. Carmel R, Jacobsen DW (2001) (eds) Homocysteine in health and disease. Cambridge University Press, New York
13. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
14. Cripps C, Burnell M, Jolivet J et al (1999) Phase II study of first-line LY231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 10:1175-1179
15. Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495
16. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-4721
17. Goedhals L, van Wijk AL (1998) MTA (LY231514) in advanced carcinoma of the cervix. Ann Oncol 9(suppl 4):70
18. Grindey GB, Alati T, Shih C (1991) Reversal of the toxicity but not the antitumor activity of lometrexol by folic acid. Proc Am Assoc Cancer Res 32:324
19. Grindey GB, Shih C, Barnett CJ et al (1992) LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res 33:411
20. Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6:363-373
21. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597
22. Homocysteine Lowering Trialists' Collaboration (1998) Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 316:894-898
23. Laohavinij S, Wedge SR, Lind MJ et al (1996) A phase I clinical study of the antipurine antifolate lomotrexol (DDATHF) given with oral folic acid. Invest New Drugs 14:325-335
24. Latz JE, Chaudhary A, Ghosh A, Johnson RD (2006) Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 57. DOI 10.1007/s00280-005-0036-1
25. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD (2006) Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57. DOI 10.1007/s00280-005-0035-2
26. Maas H (2001) Development of a semi-physiological population PK/PD model of hematological toxicity: evaluation of across-drug consistency. MSc Thesis. Uppsala University. Uppsala, Sweden
27. Mackiewicz A, Speroff T, Ganapathi MK, Kushner I (1991) Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 146:3032-3037
28. Maes M, Stevens W, Scharpe S et al (1994) Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6 and soluble interleukin-2 and -6 receptor concentrations in normal volunteers. Experientia 50:821-829
29. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20:511-528
30. McKenzie SB (1996) Textbook of hematology. Williams and Wilkins, Baltimore, pp 22-29, pp 58-67
31. Mentre F, Ebelin ME (1997) Validation of population pharmacokinetic/ pharmacodynamic analyses: review of proposed approaches. In: Balant LP, Aarons L (eds) The population approach: measuring and managing variability in response, concentration and dose. Commission of the European Communities, Brussels, pp 147-160
32. Miller KD, Picus J, Blanke C et al (2000) Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11:101-103
33. Moran RG (1999) Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 26(2 suppl 6):24-32
34. Niyikiza C, Baker SD, Seitz DE et al (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545-552
35. Niyikiza C, Hanauske AR, Rusthoven JJ et al (2002) Pemetrexed safety and dosing strategy. Semin Oncol 29(6 Suppl 18):24-29
36. Odamaki M, Kato A, Kumagai H, Hishida A (2004) Counter-regulatory effects of procalcitonin and indoxyl sulphate on net albumin secretion by cultured rat hepatocytes. Nephrol Dial Transplant 19:797-804
37. O'Dwyer PJ, Nelson K, Thornton DE (1999) Overview of phase II trials of MTA in solid tumors. Semin Oncol 26:99-104
38. Paz-Ares L, Tabernero J, Moyano A et al (1999) Significant activity of the multitargeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: results of a phase II trial. Eur J Cancer 35(suppl 2):S81
39. Pivot X, Raymond E, Laguerre B et al (2001) Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 85:649-655
40. Rinaldi DA, Kuhn JG, Burris HA et al (1999) A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372-380
41. Rusthoven JJ, Eisenhauer E, Butts C et al (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: a phase II study National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:1194-1199
42. Sandström M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO (2005) Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23:413-421
43. SAS Institute Inc (1997) SAS/STAT software: changes and enhancements through release 6.12. Cary, NC: SAS Institute Inc
44. 12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21:1556-1561
45. Shargel L, Yu ABC (1985) Applied biopharmaceutics, 2nd edn. Appleton-Century-Crofts, Norwalk, pp 310-312
46. Sheiner LB (1986) Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals. J Pharmacokinet Biopharm 14:539-555
47. Sheiner LB, Steimer JL (2000) Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67-95
48. Shih C, Gosset L, Gates S et al (1996) LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS): multiple folate enzyme inhibition. Ann Oncol 7(Suppl 1):85
49. Spielmann M, Martin M, Namer M, duBois A, Unger C, Dodwell DJ (2001) Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2:47-51
50. Stabler SP, Lindenbaum J, Savage DG, Allen RH (1993) Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 81:3404-3413
51. Sun H, Fadiran EO, Jones CD et al (1999) Population pharmacokinetics. A regulatory perspective. Clin Pharmacokinet 37: 41-58
52. Suwa T, Hogg JC, English D, Van Eeden SF (2000) Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol 279:H2954-H2960
53. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644
54. Wedge SR, Laohavinij S, Taylor GA, Boddy A, Calvert AH, Newell DR (1995) Clincial pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lomotrexol) administered with an oral folic acid supplement. Clin Cancer Res 1:1479-1486
55. Yoshioka M, Mori Y, Miyazaki S, Miyamoto T, Yokomizo Y, Nakajima Y (1999) Biological functions of recombinant bovine interleukin 6 expressed in a baculovirus system. Cytokine 11:863-868